Literature DB >> 7367491

[Studies on elimination of silymarin in cholecystectomized patients. I. Biliary and renal elimination after a single oral dose].

P J Flory, G Krug, D Lorenz, W H Mennicke.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7367491     DOI： 10.1055/s-2008-1074867

Source DB:  PubMed          Journal:  Planta Med        ISSN： 0032-0943            Impact factor:   3.352


× No keyword cloud information.
  6 in total

Review 1.  The use of silymarin in the treatment of liver diseases.

Authors:  R Saller; R Meier; R Brignoli
Journal:  Drugs       Date:  2001       Impact factor: 9.546

2.  Pharmacokinetic studies on IdB 1016, a silybin- phosphatidylcholine complex, in healthy human subjects.

Authors:  N Barzaghi; F Crema; G Gatti; G Pifferi; E Perucca
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Oct-Dec       Impact factor: 2.441

3.  Comparative pharmacokinetics of silipide and silymarin in rats.

Authors:  P Morazzoni; A Montalbetti; S Malandrino; G Pifferi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1993 Jul-Sep       Impact factor: 2.441

Review 4.  Silymarin as a Natural Antioxidant: An Overview of the Current Evidence and Perspectives.

Authors:  Peter F Surai
Journal:  Antioxidants (Basel)       Date:  2015-03-20

Review 5.  Silymarin (milk thistle extract) as a therapeutic agent in gastrointestinal cancer.

Authors:  Maryam Fallah; Amirhossein Davoodvandi; Shahin Nikmanzar; Sarehnaz Aghili; Seyed Mohammad Ali Mirazimi; Michael Aschner; Amir Rashidian; Michael R Hamblin; Mohsen Chamanara; Navid Naghsh; Hamed Mirzaei
Journal:  Biomed Pharmacother       Date:  2021-08-13       Impact factor: 6.529

6.  Silymarin as Supportive Treatment in Liver Diseases: A Narrative Review.

Authors:  Anton Gillessen; Hartmut H-J Schmidt
Journal:  Adv Ther       Date:  2020-02-17       Impact factor: 3.845
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.